LDX.AU Lumos Diagnostics Holdings Ltd
- Market cap
- AUD 59.3M
- P/E
- -
- P/B
- 1.83x
- ROE
- -1.2%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is LDX.AU undervalued?
Graham numberThe Graham number of Lumos Diagnostics Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lumos Diagnostics Holdings Ltd fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-1.2%), below 10%.
ROA 0/1
Return on assets (-0.7%) is below the industry median (-0.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (41.1%) is above the industry median (-1.5%).
Revenue Growth 1/2
Revenue grew 8.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (26.0%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.8x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Lumos Diagnostics Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is he…
Full company profileLumos Diagnostics Holdings Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lumos Diagnostics Holdings Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.92M | 4.48M | 5.79M | 18.9M | 11.6M | 10.5M | 11.1M | 12.5M | 13.5M | 27.9M |
| Gross Profit | 839K | 2.04M | 2.51M | 8.60M | 4.46M | 5.32M | 7.10M | 7.91M | -7.91M | -18.6M |
| Operating Income | -1.29M | -2.89M | -10.7M | -11.0M | -23.9M | -6.56M | -7.12M | -7.84M | -14.4M | -30.0M |
| EBITDA | -1.13M | -2.41M | -10.2M | -10.6M | -24.1M | -4.87M | -5.33M | -4.73M | -11.8M | -25.0M |
| Net Income | -1.27M | -4.60M | -9.28M | -15.0M | -45.7M | -8.97M | -8.59M | -7.18M | -5.06M | -284K |
| EPS | -0.08 | -0.27 | -0.42 | -0.10 | -0.30 | -0.04 | -0.02 | -0.01 | -0.01 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.89M | 25.4M | 30.3M | 98.0M | 36.9M | 25.4M | 26.8M | 20.8M | 40.7M | 40.7M |
| Total Liabilities | 5.91M | 13.7M | 8.12M | 39.7M | 19.1M | 15.9M | 19.7M | 14.7M | 17.9M | 17.9M |
| Shareholders' Equity | 2.98M | 11.7M | 22.2M | 58.3M | 17.9M | 9.50M | 7.11M | 6.16M | 22.9M | 22.9M |
| Cash & Short-term Investments | 243K | 3.07M | 851K | 44.9M | 7.98M | 3.02M | 6.48M | 1.96M | 15.4M | 15.4M |
| Total Debt | 5.13M | 10.4M | 4.11M | 9.57M | 7.19M | 9.79M | 8.06M | 6.99M | 5.94M | 5.94M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -289K | -3.03M | -3.76M | -10.9M | -18.0M | -9.64M | 946K | -9.33M | 1.04M | 768K |
| Capital Expenditure | 1.68M | 2.53M | 6.52M | 5.88M | 4.36M | 155K | 98.0K | 53.0K | 2.59M | 9.22M |
| Free Cash Flow | -1.97M | -5.56M | -10.3M | -16.8M | -22.4M | -9.79M | 848K | -9.39M | -1.56M | -8.45M |
| Ratios | ||||||||||
| ROE | -42.5% | -39.4% | -41.9% | -25.8% | -255.7% | -94.5% | -120.9% | -116.7% | -22.1% | -1.2% |
| ROA | -14.2% | -18.1% | -30.6% | -15.3% | -123.8% | -35.3% | -32.0% | -34.5% | -12.4% | -0.7% |
| Net Profit Margin | -66.0% | -102.6% | -160.2% | -79.7% | -393.2% | -85.2% | -77.2% | -57.5% | -37.5% | -1.0% |
| Debt to Equity | 1.72x | 0.89x | 0.19x | 0.16x | 0.40x | 1.03x | 1.13x | 1.13x | 0.26x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lumos Diagnostics Holdings Ltd dividends
Lumos Diagnostics Holdings Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1281:1202 on Sep 6, 2024.
Who owns Lumos Diagnostics Holdings Ltd
- Insiders 20.65%
- Institutions 19.41%
- Public & others 59.93%
- Shares outstanding 988M
- Free float 563M
Lumos Diagnostics Holdings Ltd company profile
- Company name
- Lumos Diagnostics Holdings Ltd
- Ticker
- LDX.AU
- ISIN
- AU0000157091
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 2724 Loker Ave West, Carlsbad, CA, United States, 92010
- Phone
- 855 586 6739
- Website
- lumosdiagnostics.com
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Lumos Diagnostics Holdings Ltd management
9- Mr. Douglas WardCEO, MD & Director
- Mr. Barrie LambertChief Financial Officer
- Mr. Anthony FavaloroVice President of Quality & Operations
- Dr. Sacha Dopheide Ph.D.Chief Technology Officer
- Ms. Sarah GlubkaVice President of Human Resources
- Mr. Paul KaseChief Commercial Officer
- Ms. Tracy Weimar BA, MBACompany Secretary
- Ms. Annie BellVice President of Medical Affairs
- Amelia StephensGlobal Marketing and Awareness Consultant